From our in-house crystalline sillicon solar cell pilot line to our industry and academic partnerships, our leadership has made us the preferred gas and precursors supplier to 16 of the world’s largest solar cell manufacturers.
R&D is enhancing Air Separation Unit (ASU) competitiveness by reducing energy costs through improvements to process and equipment design, and Real Time Optimization (RTO) for on-line automatic optimization of ASU operations.
Air Liquide is expanding the global network of hydrogen refueling stations for clean electric vehicles. In R&D, we are leading the way in safe hydrogen, advanced storage solutions and fuel cells. By 2020, 50% of our H2 for energy applications will be produced through carbon-free processes.
Our Cryocap™ Oxy unit uses oxycombustion technology to capture and store pure CO2. This technology will enable the world’s first industrial scale demonstration of a zero CO2 emission coal-fired power plant.
From hospital to home, Air Liquide protects vulnerable lives throughout the world. Our telemonitoring system, NOWAPI™*, registers data on patient compliance. Meanwhile, our TAKEO™ medical oxygen cylinder with its digital gauge, allows for better planning, enabling hospital staff to devote more time to patient care.
*Manufactured by Air Liquide Medical Systems S.A. According to the European regulation, this health product is a medical device class IIa, and is CE marked. CE0459. Read carefully the instruction manual. May 11th 2015.
Air Liquide invents and evaluates new molecules for thin film technology, used by semiconductor manufacturers worldwide to improve mobile device connectivity and performance.
Air Liquide is reducing total cost of ownership of Rectisol® plants by optimizing the process to convert coal to syngas for the chemicals and fuels industry.